How much of a problem is too much saliva for patients following head and neck cancer.


Journal

The British journal of oral & maxillofacial surgery
ISSN: 1532-1940
Titre abrégé: Br J Oral Maxillofac Surg
Pays: Scotland
ID NLM: 8405235

Informations de publication

Date de publication:
11 2020
Historique:
received: 29 02 2020
accepted: 28 05 2020
pubmed: 12 7 2020
medline: 22 12 2020
entrez: 12 7 2020
Statut: ppublish

Résumé

The aim of this paper is to report the clinical characteristic of those patients reporting "I have too much saliva" following treatment for head and neck cancer. As a new addition to the saliva question of the University of Washington quality of life questionnaire (UW-QoL), another aim is to make recommendations on how this new option should be scored and handled. Patients treated with curative intent were recruited between April 2017 and October 2019. Assessment was at the first baseline clinic a median (IQR) of 194 (125-249) days after diagnosis and 103 (71-162) days after the end of treatment. Patients completed the modified UW-QoL version 4, the Patient Concerns Inventory (PCI), Distress Thermometer, and the EQ-5D-5L. In 288 patients, saliva was of normal consistency for 80 (28%), less than normal but enough for 57 (20%), too little for 91 (32%), too much for 45 (16%), and there was no saliva at all for 15 (5%). Of patients with too much saliva, two-thirds (31/45, 69%) had tumours located in the oral cavity and 18/40 (45%) had the highest rates of free flap use during surgery. Salivation response was associated strongly with the other measures of health-related quality of life (HRQoL) and the PCI. Of those with too much saliva their results were similar to or worse than those with too little or no saliva at all. In conclusion, having too much saliva is relatively less frequently reported but is an important HRQoL consideration. Its scoring in the UW-QoL should be at a level similar to that of too little saliva.

Identifiants

pubmed: 32651015
pii: S0266-4356(20)30257-6
doi: 10.1016/j.bjoms.2020.05.033
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e51-e56

Subventions

Organisme : Department of Health
ID : PB-PG-0215-36047
Pays : United Kingdom

Informations de copyright

Copyright © 2020 The British Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Auteurs

Damian Broderick (D)

Liverpool Head and Neck Centre, Aintree University Hospital, Lower Lane, Liverpool, UK. Electronic address: broderd@tcd.ie.

Derek Lowe (D)

Astraglobe Ltd, UK. Electronic address: astraglobeltd@btconnect.com.

Anastasios Kanatas (A)

Leeds Teaching Hospitals and St James Institute of Oncology and Leeds Dental Institute. Electronic address: simonn.rogers@aintree.nhs.uk.

Simon N Rogers (S)

Evidence-Based Practice Research Centre (EPRC), Faculty of Health and Social Care, Edge Hill University, St Helens Road, Ormskirk, and Consultant Regional Maxillofacial Unit, Aintree University Hospital, Lower Lane, Liverpool, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH